

Position on Prevention of Misuse and Abuse of Medicines for Doping in Sport

Background

Abuse of medicines to enhance performance in sports is considered a serious public health issue by the sport associations and public authorities worldwide. Doping in sport relies primarily on the misuse and abuse of commercially available medicines as well as those in development.

In 2010, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a Joint Declaration on Cooperation in the Fight against Doping in Sport. This has been further substantiated by the launch of the brochure of 2 FIELDS 1 GOAL: Protecting the Integrity of Science and Sport*¹, that aims to achieve the goals of this joint declaration. Together with the launch of the brochure, WADA has released a booklet titled the Points to Consider: Identification of Compounds with Potential for Doping Abuse and Sharing of Information with WADA*². These 2 documents provide guidance on how the pharmaceutical industry can support WADA in their fight against the use of doping in sport.

Our Position

Astellas supports this global initiative and is committed to meet its social responsibility in this field. Therefore, Astellas has signed a Memorandum of Understanding with WADA to contribute to the fight against doping and in this way contribute to improving public health. Astellas commits to cooperate with WADA in the following ways:

- Identifying compounds in development with a potential for sport-related doping abuse
- Cooperating to share relevant information on compounds with doping potential with WADA to support WADA in their development of detection methods for these compounds
- Minimizing the risk of misuse of compounds with doping potential during clinical trials to avoid opportunities for abuse
- Collaborating with WADA on appropriate communication plans when compounds developed by Astellas are associated with doping cases.

References

1. 2 Fields 1 Goal: Protecting the Integrity of Science and Sport
http://www.ifpma.org/wp-content/uploads/2016/01/FINAL_2_FIELDS_1_GOAL_Brochure-071612.pdf
2. Points to Consider: Identification of Compounds with Potential for Doping Abuse and Sharing of Information with WADA
http://www.ifpma.org/wp-content/uploads/2016/01/FINAL_2_FIELDS_1_GOAL_Points_to_Consider_Booklet_20120717_.pdf